Benzodiazepine choice and polydrug use

Active Project Grant Awarded Last action

Award ID
R01DA054177
Recipient
Awarding agency
Obligated
$7,041,920

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 95% complete
Place of performance
Jackson, MS 39216, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Benzodiazepines (BZS) are effective and safe when used appropriately, but their utility is limited by unwanted side effects like misuse and reduced safety when combined with other drugs. Individuals with substance-use disorders (suds) misuse BZS as much as 20X greater than the general population, and the rising number of overdose deaths attributed to BZS are largely driven by opioid CO-administration. Given the high rates of polydrug use among individuals who also misuse BZS, preclinical evaluations of BZS should consider the polydrug scenarios in which they are being misused. The goal of this research is to identify pharmacological determinants of BZ misuse, with the goal of identifying BZ-type ligands with reduced abuse potential in polydrug situations. We reported previously that nonselective, partial-efficacy BZ ligands or those that lack intrinsic efficacy at A1- subunit containing gabaa (A1GABAA) receptors have reduced abuse potential relative to traditional BZS. However, our data suggest that the degree to which these BZ-type ligands exhibit abuse potential depends on the subject's drug history. This new application will use choice models to evaluate the overall hypothesis that drug experience is a key determinant of the role of gabaa receptor subtypes in the abuse potential of BZ-type ligands. A key finding from our choice research is that efficacy at A1GABAA receptors may be necessary for self- administration of BZS in cocaine-experienced subjects, but not required for enhancement of cocaine choice. IT is unknown whether this pattern of effects is observed with other drugs of abuse, in particular opioids. Moreover, the pharmacological mechanism underlying these effects is unknown, with possibilities including (1) a differential role for A1GABAA receptors in reinforcement-enhancing VS. Reinforcing effects of BZS alone, or (2) differences in overall intrinsic efficacy, irrespective of subtype selectivity. We will address these potential mechanisms in two aims organized by unique approaches. In aim 1, we will use drug VS. Drug choice to evaluate the extent to which BZ-type ligands varying in efficacy and selectivity will enhance or attenuate drug choice when delivered as a combination with cocaine, heroin, or alprazolam in separate groups of subjects. In aim 2, we will use drug VS. Nondrug choice to evaluate the hypothesis that nonselective, partial modulators or A1-sparing BZS will have reduced reinforcing effects when delivered alone in subjects with a history of cocaine, heroin, alprazolam, or food choice. A significant addition to our groups of monkeys with different reinforcement histories will be the food-experienced animals, providing a quantitative model of drug-naïve individuals' initial exposure to drug taking. BZ use among individuals with a SUD, in or out of treatment, is increasingly common and is associated with increased risk of BZ misuse and overdose. Testing the hypotheses proposed will provide critical information for understanding how past and current drug use affects the abuse liability of BZ-type drugs.

Transactions

Action Obligated Date
Amendment $45,892
Amendment $413,035
Amendment $413,035
Amendment $45,892
Amendment $413,035
Amendment $413,035
Amendment $51,472
Amendment $51,472
Amendment $51,472
Amendment $463,255
Amendment $463,255
Amendment $463,255
Amendment $463,255
Amendment $544,734
Amendment $544,734
Amendment $544,734
Amendment $544,734
Amendment $555,812
Original award $555,812
Show all 19

Subawards

Subrecipient Amount Awarded
University Of Wisconsin System Benzodiazepine Choice and Polydrug Use $57,847
Mayo Clinic CACNA1C Genotype: Correlation with Brain and Blood Levels of CACNA1C and Treatment Responsiveness $33,000
University Of Wisconsin Systems Benzodiazepine Choice and Polydrug Use $57,848
University Of Texas Health Science Center At Houston $64,275

Quick answers

Who received award R01DA054177?

R01DA054177 was awarded to University Of Mississippi Medical Center by National Institute on Drug Abuse (National Institutes of Health) on April 1, 2022.

How much is award R01DA054177 worth?

$7,041,920 has been obligated on R01DA054177.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login